“…Example of these includes, DOXIL® for ovarian cancer (secondary to platinumbased therapies) 18 and HIV-associated Kaposi's sarcoma (secondary to chemotherapy), multiple myeloma (secondary); Abraxane® for advanced non-small cell lung cancer, metastatic breast cancer, and pancreatic cancer, VYXEOS® for acute myeloid leukemia, Hensify® for locally-advanced squamous cell carcinoma, Resovist® as a magnetic resonance imaging contrast agent and the list further increases with the total of more than 50 approved nanomedicine for clinical use. 15 While signicant efforts have been dedicated to engineering synthetic and biomimetic nanomedicine against cancer, 5,[7][8][9]16,[19][20][21][22][23][24][25][26][27] the studies related to the effect of NPs on enzyme receptor biochemical activity have been given less attention to envisioning its possible impact on infectious disease and immune modulation.…”